Kras as a key oncogene and therapeutic target in pancreatic cancer

Frontiers in Physiology

Volumn 4 JAN, Issue , 2014, Pages

  Collins, Meredith A ^a   di Magliano, Marina Pasca ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Kras; MAPK; Pancreatic cancer; PanIN; PI3K AKT mTOR; Therapeutics

Indexed keywords

EID: 84893468215     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00407     Document Type: Review

References (79)

1. Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., et al. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126. doi: 10.1101/gad.1158703.
2. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554. doi: 10.1016/0092-8674(88)90571-5.
3. Appels, N. M., Beijnen, J. H., and Schellens, J. H. (2005). Development of farnesyl transferase inhibitors: a review. Oncologist 10, 565-578. doi: 10.1634/theoncologist.10-8-565.
4. Ardito, C. M., Gruner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., et al. (2012). EGF receptor is required for kras-induced pancreatic tumorigenesis. Cancer Cell 22, 304-317. doi: 10.1016/j.ccr.2012.07.024.
5. Bar-Sagi, D. (1992). Mechanisms of signal transduction by Ras. Semin. Cell Biol. 3, 93-98. doi: 10.1016/S1043-4682(10)80018-2.
6. Berman, D. M., Karhadkar, S. S., Maitra, A., Montes De Oca, R., Gerstenblith, M. R., Briggs, K., et al. (2003). Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851. doi: 10.1038/nature01972.
7. Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M. C., Muthuswamy, L. B., Johns, A. L., et al. (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405. doi: 10.1038/nature11547.
8. Campbell, P. M., Groehler, A. L., Lee, K. M., Ouellette, M. M., Khazak, V., and Der, C. J. (2007). K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 67, 2098-2106. doi: 10.1158/0008-5472.CAN-06-3752.
9. Campbell, P. M., Singh, A., Williams, F. J., Frantz, K., Ulku, A. S., Kelley, G. G., et al. (2006). Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. Methods Enzymol. 407, 195-217. doi: 10.1016/S0076-6879(05)07017-5.
10. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. (1998). Increasing complexity of Ras signaling. Oncogene 17, 1395-1413. doi: 10.1038/sj.onc.1202174.
11. Carriere, C., Young, A. L., Gunn, J. R., Longnecker, D. S., and Korc, M. (2009). Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem. Biophys. Res. Commun. 382, 561-565. doi: 10.1016/j.bbrc.2009.03.068.
12. Carriere, C., Young, A. L., Gunn, J. R., Longnecker, D. S., and Korc, M. (2011). Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS ONE 6:e27725. doi: 10.1371/journal.pone.0027725.
13. Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., et al. (2012). The GDI-like solubilizing factor PDEdelta sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 14, 148-158. doi: 10.1038/ncb2394.
14. Clark, C. E., Beatty, G. L., and Vonderheide, R. H. (2009). Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 279, 1-7. doi: 10.1016/j.canlet.2008.09.037.
15. Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., and Vonderheide, R. H. (2007). Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518-9527. doi: 10.1158/0008-5472.CAN-07-0175.
16. Collins, M. A., Bednar, F., Zhang, Y., Brisset, J. C., Galban, S., Galban, C. J., et al. (2012a). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639-653. doi: 10.1172/JCI59227.
17. Collins, M. A., Brisset, J. C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., et al. (2012b). Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE 7:e49707. doi: 10.1371/journal.pone.0049707.
18. Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., et al. (2011). Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503. doi: 10.1038/nm.2344.
19. Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., et al. (2012). A central role for RAF->MEK->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2, 685-693. doi: 10.1158/2159-8290.CD-11-0347.
20. Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., et al. (2013). Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633-637. doi: 10.1038/nature12138.
21. Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., and Engelman, J. A. (2010). BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84. doi: 10.1126/scisignal.2001148.
22. Cox, A. D., and Der, C. J. (2002). Ras family signaling: therapeutic targeting. Cancer Biol. Ther. 1, 599-606.
23. Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W. G., Ji, L., et al. (2011). STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 71, 3658-3668. doi: 10.1158/0008-5472.CAN-10-3647.
24. Daniluk, J., Liu, Y., Deng, D., Chu, J., Huang, H., Gaiser, S., et al. (2012). An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J. Clin. Invest. 122, 1519-1528. doi: 10.1172/JCI59743.
25. Denicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109. doi: 10.1038/nature10189.
26. Dhillon, A. S., Hagan, S., Rath, O., and Kolch, W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290. doi: 10.1038/sj.onc.1210421.
27. Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 20411-20416. doi: 10.1073/pnas.0905833106.
28. Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562. doi: 10.1038/nrc2664.
29. Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., et al. (2013). Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23, 406-420. doi: 10.1016/j.ccr.2013.01.023.
30. Fritsch, R., De Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M. S., et al. (2013). RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050-1063. doi: 10.1016/j.cell.2013.04.031.
31. Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernandez-Porras, I., Canamero, M., et al. (2011). Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728-739. doi: 10.1016/j.ccr.2011.05.011.
32. Guerra, C., Schuhmacher, A. J., Canamero, M., Grippo, P. J., Verdaguer, L., Perez-Gallego, L., et al. (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302. doi: 10.1016/j.ccr.2007.01.012.
33. Gus-Brautbar, Y., Johnson, D., Zhang, L., Sun, H., Wang, P., Zhang, S., et al. (2012). The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol. Cell 45, 610-618. doi: 10.1016/j.molcel.2012.01.006.
34. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435. doi: 10.1038/nature08833.
35. Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221. doi: 10.1016/j.cell.2009.12.040.
36. Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450. doi: 10.1016/S1535-6108(03)00309-X.
37. Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483. doi: 10.1016/j.ccr.2005.04.023.
38. Hofmann, I., Weiss, A., Elain, G., Schwaederle, M., Sterker, D., Romanet, V., et al. (2012). K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS ONE 7:e44146. doi: 10.1371/journal.pone.0044146.
39. Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248. doi: 10.1101/gad.943001.
40. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., et al. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156.
41. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806. doi: 10.1126/science.1164368.
42. Kanda, M., Matthaei, H., Wu, J., Hong, S. M., Yu, J., Borges, M., et al. (2012). Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142, 730-733. doi: 10.1053/j.gastro.2011.12.042.
43. Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., Macdonald, R. J., and Wright, C. V. (2002). The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128-134. doi: 10.1038/ng959.
44. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., Desolms, S. J., et al. (1995). Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1, 792-797. doi: 10.1038/nm0895-792.
45. Kothari, V., Wei, I., Shankar, S., Kalyana-Sundaram, S., Wang, L., Ma, L. W., et al. (2013). Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov. 3, 280-293. doi: 10.1158/2159-8290.CD-12-0336.
46. Laheru, D., Shah, P., Rajeshkumar, N. V., Mcallister, F., Taylor, G., Goldsweig, H., et al. (2012). Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest. New Drugs 30, 2391-2399. doi: 10.1007/s10637-012-9818-6.
47. Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., et al. (1993). Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328, 1433-1437. doi: 10.1056/NEJM199305203282001.
48. Lu, X., Xu, T., Qian, J., Wen, X., and Wu, D. (2002). Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin. Med. J. (Engl) 115, 1632-1636.
49. Malka, D., Hammel, P., Maire, F., Rufat, P., Madeira, I., Pessione, F., et al. (2002). Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 51, 849-852. doi: 10.1136/gut.51.6.849.
50. Morris, J. P. T., Cano, D. A., Sekine, S., Wang, S. C., and Hebrok, M. (2010a). Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508-520. doi: 10.1172/JCI40045.
51. Morris, J. P. T., Wang, S. C., and Hebrok, M. (2010b). KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683-695. doi: 10.1038/nrc2899.
52. Navas, C., Hernandez-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., and Barbacid, M. (2012). EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318-330. doi: 10.1016/j.ccr.2012.08.001.
53. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., Mcintyre, D., Honess, D., et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461. doi: 10.1126/science.1171362.
54. Olive, K. P., and Tuveson, D. A. (2006). The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res. 12, 5277-5287. doi: 10.1158/1078-0432.CCR-06-0436.
55. Parsons, B. L., and Meng, F. (2009). K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark. Med. 3, 757-769. doi: 10.2217/bmm.09.95.
56. Patgiri, A., Yadav, K. K., Arora, P. S., and Bar-Sagi, D. (2011). An orthosteric inhibitor of the Ras-Sos interaction. Nat. Chem. Biol. 7, 585-587. doi: 10.1038/nchembio.612.
57. Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390. doi: 10.1038/nature10662.
58. Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774. doi: 10.1038/nrc3106.
59. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., et al. (2009). A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500. doi: 10.1016/j.ccr.2009.03.022.
60. Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., et al. (2010). Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593. doi: 10.1038/nbt.1640.
61. Singh, M., and Maitra, A. (2007). Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 7, 9-19. doi: 10.1159/000101873.
62. Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J., and Bos, J. L. (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16, 7773-7782. doi: 10.1093/nar/16.16.7773.
63. Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., et al. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105. doi: 10.1038/nature12040.
64. Thayer, S. P., Di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., et al. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856. doi: 10.1038/nature02009.
65. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341. doi: 10.1038/nrm2882.
66. Vigil, D., Cherfils, J., Rossman, K. L., and Der, C. J. (2010). Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842-857. doi: 10.1038/nrc2960.
67. Vonderheide, R. H., and Bayne, L. J. (2013). Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol. 25, 200-205. doi: 10.1016/j.coi.2013.01.006.
68. Walters, D. M., Lindberg, J. M., Adair, S. J., Newhook, T. E., Cowan, C. R., Stokes, J. B., et al. (2013). Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 15, 143-155. doi: 10.1593/neo.121712.
69. Weisz, B., Giehl, K., Gana-Weisz, M., Egozi, Y., Ben-Baruch, G., Marciano, D., et al. (1999). A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18, 2579-2588. doi: 10.1038/sj.onc.1202602.
70. Whitcomb, D. C., and Pogue-Geile, K. (2002). Pancreatitis as a risk for pancreatic cancer. Gastroenterol. Clin. North Am. 31, 663-678. doi: 10.1016/S0889-8553(02)00004-3.
71. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., et al. (1997). K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464. doi: 10.1074/jbc.272.22.14459.
72. Williams, T. M., Flecha, A. R., Keller, P., Ram, A., Karnak, D., Galban, S., et al. (2012). Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol. Cancer Ther. 11, 1193-1202. doi: 10.1158/1535-7163.MCT-12-0098.
73. Yakubovskaya, M. S., Spiegelman, V., Luo, F. C., Malaev, S., Salnev, A., Zborovskaya, I., et al. (1995). High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int. J. Cancer 63, 810-814. doi: 10.1002/ijc.2910630611.
74. Yan, L., Mcfaul, C., Howes, N., Leslie, J., Lancaster, G., Wong, T., et al. (2005). Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128, 2124-2130. doi: 10.1053/j.gastro.2005.03.006.
75. Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., et al. (2008). A paracrine requirement for hedgehog signalling in cancer. Nature 455, 406-410. doi: 10.1038/nature07275.
76. Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670. doi: 10.1016/j.cell.2012.01.058.
77. Zhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., et al. (2013a). Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73, 6359-6374. doi: 10.1158/0008-5472.CAN-13-1558-T.
78. Zhang, Y., Morris, J. P. T., Yan, W., Schofield, H. K., Gurney, A., Simeone, D. M., et al. (2013b). Canonical Wnt signaling Is required for pancreatic carcinogenesis. Cancer Res. 73, 4909-4922. doi: 10.1158/0008-5472.CAN-12-4384.
79. Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., et al. (2013). Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497, 638-642. doi: 10.1038/nature12205.